<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560751</url>
  </required_header>
  <id_info>
    <org_study_id>Prolong</org_study_id>
    <nct_id>NCT04560751</nct_id>
  </id_info>
  <brief_title>TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)</brief_title>
  <official_title>TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma：A Multicenter, Single-armed, Prospective, Observational Study (Prolong)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, observational study in which subjects will be treated&#xD;
      with lenvatinib combined with TACE in un-resectable HCC patients who had not received&#xD;
      systematic treatment or TACE treatment in the past.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only 30% of HCC patients received radical resection. Most of the patients are in the advanced&#xD;
      stage and can only receive palliative treatment such as TACE or systemic treatment.&#xD;
      Lenvatinib is a multi-target receptor tyrosine kinase inhibitor (TKI), which mainly inhibits&#xD;
      vascular endothelial growth factor(VEGF) receptor-1, 2, 3; fibroblast growth factors(FGF)&#xD;
      receptor-1, 2, 3, 4; platelet derived growth factor receptor(PDGFR)α; RET and KIT and showed&#xD;
      significant anti-tumor effect in REFLECT study. The purpose of this study is to explore the&#xD;
      efficacy and safety of Lenvatinib and TACE in unresectable HCC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate（ORR）</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic ORR and Extrahepatic ORR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The percentage of patients who have best overall response of complete response (CR) or partial response (PR) according to mRECIST intrahepatic or extrahepatic, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The time from the beginning of treatment of TACE to the time of tumor progression or death from any cause (according to mRECIST standard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-fetoprotein (AFP) response rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>A decrease in AFP of more than 20% in AFP+ patients treated with lenvatinib is defined as an AFP response.AFP response rate defined as the percentage of AFP response patients in all AFP positive patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression（TTP）</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The time from the beginning of treatment of TACE to the time of tumor progression. (according to mRECIST standard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AEs)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>AEs(adverse events) evaluated by the CTC-AE 5.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Lenvatinib and TACE</arm_group_label>
    <description>Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib capsules will be administered orally, once daily (for patients &lt;60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)</description>
    <arm_group_label>Lenvatinib and TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE will be performed as needed.</description>
    <arm_group_label>Lenvatinib and TACE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Unrecestable CNLC stage IIb-IIIb HCC patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages of ≥ 18 and ≤ 75 years old.&#xD;
&#xD;
          2. Clinically or histopathologically diagnosed as hepatocellular carcinoma (HCC).&#xD;
&#xD;
          3. China stage IIb-IIIb patients, not suitable for surgical resection.&#xD;
&#xD;
          4. The imaging examination within 2 weeks before interventional therapy showed that there&#xD;
             was at least one target lesion that could be measured by CT or MRI, and the lesion was&#xD;
             suitable for repeated and accurate measurement.&#xD;
&#xD;
          5. Child-Pugh scores ≤7.&#xD;
&#xD;
          6. ECOG：0-1.&#xD;
&#xD;
          7. Intended to be treated with TACE combined with lenvatinib.&#xD;
&#xD;
          8. Good organ and bone marrow function: Blood routine: WBC&gt;4.0×109/L、Hb&gt;80g/L,&#xD;
             PLT&gt;75×109/L, NEUT&gt;1.5×10⁹/L. Blood coagulation function: International normalized&#xD;
             ratio (INR)&lt;1.2. Hepatic function: serum albumin (ALB)&gt;3.5 g/dl, total bilirubin&#xD;
             (TBIL) &lt;1.5 × normal upper limit (ULN) (Eliminate biliary obstruction), alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 3 × ULN. Renal&#xD;
             dysfunction：serum creatinine (SCR) &lt;1.5× ULN.&#xD;
&#xD;
          9. Agreed to join the clinical trial and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatobiliary cell carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular&#xD;
             carcinoma.&#xD;
&#xD;
          2. With invasion of the main portal vein or vena cava.&#xD;
&#xD;
          3. Received interventional therapy such as TACE within 2 years.&#xD;
&#xD;
          4. Received systematic treatment in the past.&#xD;
&#xD;
          5. Uncontrollable ascites, hepatic encephalopathy or esophagogastric variceal bleeding.&#xD;
&#xD;
          6. Patients with hypertension who cannot be reduced to normal range after&#xD;
             antihypertensive treatment (systolic blood pressure &gt; 140mmHg, or diastolic blood&#xD;
             pressure &gt; 90 mmHg).&#xD;
&#xD;
          7. Suffering from grade II or above myocardial ischemia or myocardial infarction, poorly&#xD;
             controlled arrhythmia or myocardial ischemia or myocardial infarction (The QTc&#xD;
             interval ≥ 450ms, QTc interval is calculated by Fridericia formula).&#xD;
&#xD;
          8. There is a history of gastrointestinal bleeding or a clear tendency of&#xD;
             gastrointestinal bleeding in the past 3 months, such as esophageal varices at risk of&#xD;
             bleeding, local active ulcer lesions, fecal occult blood ≥ (+).&#xD;
&#xD;
          9. Pregnant or lactating women. A fertile patient who is unwilling or unable to use&#xD;
             effective contraception.&#xD;
&#xD;
         10. Patients with HIV infection.&#xD;
&#xD;
         11. Suspected allergy to research drugs.&#xD;
&#xD;
         12. Other situations which the researchers considered ineligible for participating in the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoliang Shao, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoliang Shao, Professor</last_name>
    <phone>13989898089</phone>
    <email>zenghuiray@163.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>guoliang shao</investigator_full_name>
    <investigator_title>Vice President of Zhejiang Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>Transarterial chemoembolization</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

